Clinical trials have always been complex. But in recent years, that complexity has accelerated.
Protocols are more detailed, eligibility criteria are more precise, and data requirements continue to expand. At the same time, timelines remain under pressure, and the cost of delays continues to rise.
For clinical development teams, the challenge is no longer understanding these pressures. It’s finding ways to move faster, make better decisions, and execute with greater confidence inside increasingly complex systems.
This is where artificial intelligence is starting to have a measurable impact.
AI is no longer a future capability or a standalone innovation but is already being applied across clinical trials to improve how studies are designed, how patients are identified, and how execution is managed — with clear implications for timelines, cost, and overall performance.
Why Clinical Trials Are Reaching a Breaking Point
Today, the clinical trial process struggles to effectively manage the increased level of complexity organizations are now working within.
Teams are expected to bring together clinical data, operational data, and real-world evidence to make more informed decisions across the trial lifecycle. In practice, these data sources are often fragmented, stored across different systems, and difficult to align. As a result, critical decisions are slowed down by manual processes and incomplete visibility, limiting teams’ ability to move trials forward with speed and confidence.
This shows up in familiar ways:
- Study designs that require multiple revisions after launch.
- Recruitment strategies that fail to reach target populations.
- Site selection decisions based on limited or outdated data.
- Trial monitoring processes that react to issues rather than anticipate them.
Each of these challenges introduces delays, increases cost, and adds risk. Across a portfolio of trials, the impact compounds quickly.
AI is Shifting From Analysis to Action
What is changing is not just the availability of AI, but how it’s being used. Historically, AI has been applied as an analytical layer and something that helps teams understand what has already happened.
Instead of sitting outside the process, AI is becoming part of how decisions are made and actions are taken. By connecting data, reducing manual effort and enabling real-time insight, it helps teams operate with greater clarity and coordination, all in service of the bigger goal: discovering treatments faster while helping control the rising cost of development.
This important shift is being enabled by several developments:
- The ability to integrate clinical, operational, and real-world datasets.
- Advances in predictive modeling that support scenario testing.
- Agentic AI workflows that automate multi-step processes.
- Platforms that connect insights directly to execution.
Organizations with access to datasets spanning tens of millions of patient records are able to train more robust models, improving both the accuracy of insights and their applicability in clinical decision-making.
Where AI Is Already Making a Difference
Across the clinical trial lifecycle, there are several areas where AI is already delivering measurable value.
Study Design and Feasibility
Before a study begins, AI can evaluate protocols against real-world patient populations and historical trial data.
This allows teams to identify feasibility risks earlier, test different scenarios, and refine study design before launch. By addressing these issues upfront, organizations can reduce the likelihood of protocol amendments and avoid downstream delays.
Patient Recruitment and Site Selection
Recruitment remains one of the most persistent challenges in clinical trials.
AI improves this process by helping teams identify patient populations more precisely and match them to sites with the highest likelihood of successful enrollment.
It also enhances site selection by incorporating both historical performance and real-time data, allowing teams to prioritize sites that are more likely to meet enrollment targets.
Trial Execution and Monitoring
During execution, AI enables a more proactive approach to trial management.
Instead of relying on periodic reporting, teams gain continuous visibility into trial performance. Predictive models can identify emerging risks, allowing teams to intervene earlier and maintain timelines.
This shift from reactive to proactive monitoring helps reduce disruptions and improve overall trial consistency.
From Efficiency Gains To Measurable Outcomes
The impact of these changes is not incremental; it’s measurable. Organizations applying AI across clinical trial workflows are seeing:
- Faster study design and feasibility validation.
- Reduced reliance on protocol amendments.
- Improved site activation timelines.
- Higher enrollment efficiency.
- Greater predictability across trial execution.
In many cases, this translates into reducing overall trial timelines by 10 to 20 months, while also lowering operational costs and improving resource allocation.
For organizations managing multiple studies, these gains have a direct impact on pipeline progression, competitive positioning, and long-term performance.
The Role of Data in Making AI Work
AI doesn’t operate in isolation, and its effectiveness depends on the quality and structure of the underlying data.
Clinical, operational, and real-world datasets need to be integrated in a way that supports consistent, reliable analysis. Without this foundation, even the most advanced AI models are limited in their ability to deliver meaningful results.
When data is connected effectively, AI can provide:
- A unified view of trial performance.
- More accurate patient and site selection.
- Deeper feasibility and risk insights.
- Scalable workflows that reduce manual effort.
This combination of data integration, predictive modeling, and workflow automation is becoming a defining feature of modern clinical development.
What This Means for Clinical Teams
For clinical development and operations teams, AI is not replacing expertise, but simply augmenting it. By reducing manual processes and improving access to insights, AI allows teams to spend less time gathering information and more time acting on it.
This changes how teams operate day to day:
- Decisions can be made faster and with greater confidence.
- Study designs can be refined earlier in the process.
- Risks can be identified and addressed before they escalate.
- Resources can be allocated more effectively across trials.
Over time, this leads to more consistent execution and stronger overall performance.
Moving From Potential To Practice
As the industry approaches the 2026 ASCO® Annual Meeting, the conversation around AI is continuing to evolve. The focus is no longer on what AI could do. It’s on what it is already doing.
Organizations are moving beyond isolated tools and pilot projects, looking instead for integrated approaches that connect data, AI, and workflows in a way that delivers measurable outcomes.
This reflects a broader transition from experimentation to execution, and from insight to impact.
Take the Next Step
AI is already improving how clinical trials are designed, executed, and optimized.
To explore how these capabilities are being applied in practice, access ConcertAI insights and research.
And, be sure to connect with our team at the Annual Meeting.